Stay updated on Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Sign up to get notified when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.

Latest updates to the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page
- Check3 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2 in the site metadata.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedAdded B-cell chronic lymphocytic leukemia as a keyword/condition term and included Genetic and Rare Diseases Information Center as a resources entry. These updates improve searchability and provide readers with additional background information.SummaryDifference0.2%

- Check24 days agoChange DetectedThe page's revision history now shows the addition of v3.5.0 and the removal of v3.4.3.SummaryDifference0.1%

- Check38 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check67 days agoChange DetectedAdded Revision: v3.4.2. The prior funding-status notice and Revision: v3.4.1 were removed.SummaryDifference0.5%

- Check74 days agoChange DetectedAdded a government funding notice noting potential delays in updates and the NIH Clinical Center's status, with guidance to check cc.nih.gov and opm.gov. Updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.5%

Stay in the know with updates to Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cirmtuzumab Consolidation after Venetoclax in CLL Clinical Trial page.